Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
- 28 May 1996
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 93 (11), 5501-5506
- https://doi.org/10.1073/pnas.93.11.5501
Abstract
The association between human immunodeficiency virus type I (HIV-1) RNA load changes and the emergence of resistant virus variants was investigated in 24 HIV-1-infected asymptomatic persons during 2 years of treatment with zidovudine by sequentially measuring serum HIV-1 RNA load and the relative amounts of HIV-1 RNA containing mutations at reverse transcriptase (RT) codons 70 (K-->R), 41 (M-->L), and 215 (T-->Y/F). A mean maximum decline in RNA load occurred during the first month, followed by a resurgence between 1 and 3 months, which appeared independent of drug-resistance. Mathematical modeling suggests that this resurgence is caused by host-parasite dynamics, and thus reflects infection of the transiently increased numbers of CD4+ lymphocytes. Between 3 and 6 months of treatment, the RNA load returned to baseline values, which was associated with the emergence of virus containing a single lysine to arginine amino acid change at RT codon 70, only conferring an 8-fold reduction in susceptibility. Despite the relative loss of RNA load suppression, selection toward mutations at RT codons 215 and 41 continued. Identical patterns were observed in the mathematical model. While host-parasite dynamics and outgrowth of low-level resistant virus thus appear responsible for the loss of HIV-1 RNA load suppression, zidovudine continues to select for alternative mutations, conferring increasing levels of resistance.Keywords
This publication has 28 references indexed in Scilit:
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDSAIDS, 1994
- Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infectionAIDS, 1994
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistanceJournal of General Virology, 1994
- Competition between zidovudine-sensitive and zidovudine-resistant strains of HIVAIDS, 1992
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Population dynamics of HIV within an individual after treatment with zidovudineAIDS, 1991
- Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapyThe Lancet, 1990
- EFFECT OF ZIDOVUDINE ON SERUM HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN LEVELS IN SYMPTOM-FREE SUBJECTSThe Lancet, 1988